Amgen Inc. Available-for-sale Securities, Amortized Cost Basis
Amgen Inc. (AMGN) had Available-for-sale Securities, Amortized Cost Basis of $32.17 billion as of 2018-03-31, per its 10-Q filed 2018-04-25.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2019-02-13
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $32.17B.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $41.45B.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $40.78B.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $38.77B.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-03-31 | $32.17B 10-Q · filed 2018-04-25 |
| 2017-12-31 | $41.45B 10-K · filed 2019-02-13 |
| 2017-09-30 | $40.78B 10-Q · filed 2017-10-26 |
| 2017-06-30 | $38.77B 10-Q · filed 2017-07-26 |
| 2017-03-31 | $38.08B 10-Q · filed 2017-04-27 |
| 2016-12-31 | $37.91B 10-K · filed 2018-02-13 |
| 2016-09-30 | $37.32B 10-Q · filed 2016-10-28 |
| 2016-06-30 | $34.24B 10-Q · filed 2016-07-29 |
| 2016-03-31 | $34.30B 10-Q · filed 2016-05-02 |
| 2015-12-31 | $31.37B 10-K · filed 2017-02-14 |
| 2015-09-30 | $30.83B 10-Q · filed 2015-11-02 |
| 2015-06-30 | $29.67B 10-Q · filed 2015-08-05 |
| 2015-03-31 | $26.48B 10-Q · filed 2015-04-27 |
| 2014-12-31 | $26.76B 8-K · filed 2016-10-31 |
| 2014-09-30 | $27.79B 10-Q · filed 2014-10-29 |
| 2014-06-30 | $25.66B 10-Q · filed 2014-08-05 |
| 2014-03-31 | $23.00B 10-Q · filed 2014-04-30 |
| 2013-12-31 | $22.43B 10-K · filed 2015-02-19 |
| 2013-09-30 | $25.66B 10-Q · filed 2013-10-29 |
| 2013-06-30 | $21.79B 10-Q · filed 2013-08-06 |
| 2013-03-31 | $20.71B 10-Q · filed 2013-05-03 |
| 2012-12-31 | $23.45B 10-K · filed 2014-02-24 |
| 2012-09-30 | $24.61B 10-Q · filed 2012-11-06 |
| 2012-06-30 | $21.64B 10-Q · filed 2012-08-08 |
| 2012-03-31 | $18.70B 10-Q · filed 2012-05-08 |
| 2011-12-31 | $19.81B 10-K · filed 2013-02-27 |
| 2011-09-30 | $17.17B 10-Q · filed 2011-11-04 |
| 2011-06-30 | $18.85B 10-Q · filed 2011-08-08 |
| 2011-03-31 | $15.09B 10-Q · filed 2011-05-10 |
| 2010-12-31 | $17.11B 10-K · filed 2012-02-29 |
| 2010-09-30 | $16.57B 10-Q · filed 2010-11-08 |
| 2010-06-30 | $14.19B 10-Q · filed 2010-08-09 |
| 2009-12-31 | $13.24B 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |